

Special Issue

Peptide Antibiotics from Microbes and Venomous Animals, 2nd Edition

Message from the Guest Editor

The first edition of the Special Issue “Peptide Antibiotics from Microbes and Venomous Animals” was published in 2020. It is a successful collection with seven excellent papers and has encouraged us to open a second edition for the same topic. As a continuation of the first Special Issue, this second edition focuses on the antibacterial peptides from microbes and venomous animals. It comprises the structural and functional characterizations of peptide antibiotics, from their early discovery to the advanced stage of clinical trials. Researchers and clinicians working with peptide antibiotics (and related compounds) are encouraged to submit their best manuscript(s) to this Special Issue, which discusses one of the most important fields of applied research.

Guest Editor

Dr. Jean-Marc Sabatier

Institute of Neurophysiopathology (INP), Aix-Marseille University,
Faculté des sciences médicales et paramédicales, 27, Bd Jean Moulin,
13005 Marseille, France

Deadline for manuscript submissions

closed (31 July 2025)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/198504

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)